Updated time: 2021-01-08 17:48:53
03A-1061103
US 10494334 B2、TW I711448
The present invention discloses a series of benzenesulfonamide (BSA) derivatives which are observed to display effective antiviral activity by significantly reducing DENV-2 and ZIKV viral protein expression and infectious viral progeny production in a dose-dependent manner in human neuronal BE(2)C cells. The invention further declares that treatments of BSA significantly improve the animal survival. The invention claims use of benzenesulfonamide (BSA) derivatives which are showed the potent antiviral effect against DENV-2 and ZIKV infections in vitro and in vivo.
- There is no antiviral drug in the drug market existing against dengue virus and Zika virus infections.
- The present invention discloses a simple synthesis method and the manufacturing process to prepare the BSA-type derivatives, with improved solubility, which significantly display therapeutic effect against DENV-2 and ZIKV infections in vitro and in vivo.
Antiviral chemotherapy for dengue virus and Zika virus infections.
Wen-Shan Li, Yi-Ling Lin, Wei-Chia Chen, Yogy Simanjuntak
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

COMPOUNDS AND METHODS FOR TREATMENT OF DENGUE AND ZIKA VIRUS INFECTION